Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report ... Chief Executive Officer David Ricks also said in January that the company expects production ...

Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...

CEO David Ricks said the company expects to produce 60% more doses of the drugs in the first half of 2025 compared to last year. Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered ...

Eli Lilly forecasts $45 billion in 2024 revenue ... During the conference, David Ricks outlined two reasons for the guidance update: The diabetes GLP market, in December, outperforms the rest ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

SAN FRANCISCO — When Eli ... that Lilly was only offering the lowest doses in vials, and the new prices, $399 or $549 a month, are still prohibitive for many patients. CEO Dave Ricks said ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...